期刊文献+

MAdCAM-1及NF-КB在小鼠恶唑酮结肠炎中的表达及一氧化氮供体的干预作用 被引量:5

Expression of MAdCAM-1 and nuclear factor kappa B and the intervention effect of nitric oxide donor in oxazoloneinduced colitis
下载PDF
导出
摘要 目的:探讨MAdCAM-1在恶唑酮结肠炎中的表达及一氧化氮供体DETA NONOate和GTN对恶唑酮结肠炎的干预作用.方法:32只C57BL/6小鼠随机分为正常对照组(A)、恶唑酮结肠炎组(B)、GTN干预组(C)和DETA NONOate干预组(D).除正常对照组外,其余3组均建立小鼠恶唑酮结肠炎模型,两个一氧化氮供体干预后处死小鼠.评价DAI、大体评分和组织学评分;免疫组织化学法检测MAdCAM-1及NF-КB;硝酸还原酶法测定血清中NO含量;测定结肠组织MPO活性.结果:B组小鼠DAI评分自灌肠之日起逐渐增高,而D组则变化不明显.B组小鼠大体评分、组织学评分、NF-КB的表达、MAdCAM-1的表达、MPO活性(3.13±0.84,20.31±2.63,30.29±8.68,17.60±6.53,3.83±0.60)均分别高于A组(0.38±0.52,0.88±0.83,7.38±2.29,4.08±1.30,1.75±0.25,P<0.01)和D组(1.38±0.52,11.13±1.48,12.60±3.54,8.42±2.16,2.76±0.48,P<0.01),而C组则与B组相近.B组小鼠血清NO浓度高于A组(54.51±22.28 vs 32.17±14.88,P<0.05),而低于D组和C组(54.51±22.28 vs 88.53±24.77,80.12±19.79,均P<0.05).B组MAdCAM-1的表达与组织学评分、MPO活性、NF-КB P65 L4值呈正相关(r=0.786,r=0.833,r=0.833,P<0.05).结论:小鼠恶唑酮结肠炎中结肠固有层MAdCAM-1的表达增加,DETA NONOate可能是治疗溃疡性结肠炎的有价值药物. AIM:To investigate the expression of MAdCAM-1 and nuclear factor kappa B(NF-КB) as well as the intervention of nitric oxide(NO) donor DETA NONOate and GTN in oxazolone-induced colitis. METHODS:Thirty two C57BL/6 mice were randomly divided into 4 groups:group A,B,C and D.The oxazolone experimental colitis model was established in group B,C and D.Mice of group C were treated with GTN and group D with DETA NONOate.The disease activity index (DAI),macroscopic score and histological score in each group were evaluated.The expression of MAdCAM-1 and NF-КB were determined by immunohistochemical staining.The plasma nitric oxide(NO)levels and the MPO activity in colonic tissues were also analyzed. RESULTS:The DAI in group B and C increased since oxazolone was administered rectally,but it did not changed obviously in group D.The macroscopic score,the histological score,the expression of NF-КB,the expression of MAd- CAM-1 and the MPO activity in group B(3.13±0.84,20.31±2.63,30.29±8.68,17.60±6.53,3.83±0.60),which were significantly higher than those in group A,respectively(0.38±0.52,0.88±0.83, 7.38±2.29,4.08±1.30,1.75±0.25,P〈0.01)and group D(1.38±0.52,11.13±1.48,12.60±3.54,8.42±2.16,2.76±0.48,P〈0.01),but similar to those of group C.The level of plasma NO in group B was significantly higher than that of group A (54.51±22.28 vs 32.17±14.88,P〈0.05),but significantly lower than that of group D and C(54.51±22.28 vs 88.53±24.77,80.12±19.79,all P〈0.05). There were significant positive correlations be- tween the expression of MAdCAM-1 and the histological score,the MPO activity and IA of NF-КB(r=0.786,r=0.833,r=0.833,P〈0.05). CONCLUSION:The expression of MAdCAM-1 increases significantly in lumina propria of colonic tissues in oxazolone-induced colitis of mice.According to these results,DETA NONO- ate may serve as a valuable biological agent for UC treatment.
出处 《世界华人消化杂志》 CAS 北大核心 2008年第6期596-601,共6页 World Chinese Journal of Digestology
关键词 恶唑酮 MADCAM-1 核因子-КB 一氯化氮 溃疡性结肠炎 Oxazolone MAdCAM-1 Nuclear factor kappa B Nitric oxide Ulcerative colitis
  • 相关文献

参考文献16

  • 1Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS,Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13- producing NK-T cells. Immunity 2002; 17:629-638.
  • 2Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
  • 3Ekstrom GM. Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid. Scand J Gastroenterol 1998; 33: 174-179.
  • 4韩英,村田有志,伊东重豪,栋方昭博.长期应用尼古丁对恶唑酮诱导的实验性小鼠肠炎模型的影响及其机制探讨[J].中华消化杂志,2001,21(8):473-476. 被引量:39
  • 5Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110.
  • 6Arihiro S, Ohtani H, Suzuki M, Murata M, Ejima C, Oki M, Kinouchi Y, Fukushima K, Sasaki I, Nakamura S, Matsumoto T, Torii A, Toda G, Nagura H. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int 2002; 52:367-374.
  • 7Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002; 51:30-36.
  • 8MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007; : CD006097.
  • 9Goto A, Arimura Y, Shinomura Y, Imai K, Hinoda Y. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis 2006; 12:758-765.
  • 10Kocaman O, Sahin T, Aygun C, Senturk O, Hulagu S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis 2006; 12:166-171.

二级参考文献3

  • 1Murata Y,Gastrointestinal Function,2000年,18卷,87页
  • 2Boirivant M,J Exp Med,1998年,188卷,1929页
  • 3Murata Y,J Gastroenterol,1995年,30卷,suppl 8期,56页

共引文献38

同被引文献65

引证文献5

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部